keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28099469/the-prevalence-of-nonalcoholic-fatty-liver-disease-and-related-metabolic-comorbidities-was-associated-with-age-at-onset-of-moderate-to-severe-plaque-psoriasis-a-cross-sectional-study
#1
Xin Xu, Lina Su, Yunlu Gao, Yangfeng Ding
Nonalcoholic fatty liver disease (NAFLD) has been found to be highly prevalent in psoriatic patients. Adult onset psoriasis could be divided into either early or late onset psoriasis. The associations between NAFLD and related metabolic comorbidities and age at onset of psoriasis have not yet been investigated. Our study was to evaluate the associations between prevalence of NAFLD and related metabolic conditions and early, late, and childhood onset psoriasis. A cross-sectional observational study was conducted on patients with moderate to severe plaque psoriasis...
2017: PloS One
https://www.readbyqxmd.com/read/28092253/-mexican-treatment-goals-for-plaque-psoriasis
#2
Lorena Estrada-Aguilar, Mario Amaya-Guerra, Minerva Gómez-Flores, Esther Guevara-Sanginés, Fermín Jurado-Santacruz, Adriana Lopeztello-Santillán, César Maldonado-García, Mónica Rivera-Gómez, Norma Rodríguez-Martínez, Luis Vega-González
Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease...
January 2017: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/28074446/efficacy-and-safety-of-switching-to-ixekizumab-in-etanercept-non-responders-a-subanalysis-from-two-phase-iii-randomized-clinical-trials-in-moderate-to-severe-plaque-psoriasis-uncover-2-and-3
#3
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, Luis Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin
BACKGROUND: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. OBJECTIVE: Our aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using a post-hoc analysis in two phase III studies. METHODS: For the subanalyses in two phase III trials (UNCOVER-2 and -3), non-response was defined by either failure to have a static physician global assessment (sPGA) of 0/1 in UNCOVER-2 or failure to have at least 75% improvement in psoriasis area and severity index (PASI 75) in UNCOVER-3 at Week 12 of each study...
January 10, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28064543/itolizumab-a-novel-anti-cd6-monoclonal-antibody-a-safe-and-efficacious-biologic-agent-for-management-of-psoriasis
#4
Sunil Dogra, Shraddha Uprety, Swaroop Hassan Suresh
Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6...
January 9, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28063039/xenotransplantation-model-of-psoriasis
#5
Jeremy Di Domizio, Curdin Conrad, Michel Gilliet
Psoriasis is a chronic autoimmune skin disease affecting approximately 2 % of the population with a major psychosocial and socioeconomic impact. A causal therapy leading to permanent cure is not available, and current treatments only lead to limited amelioration, and therefore new therapeutic targets need to be identified. Recent works demonstrated a predominant role of TH17 cells in the pathogenesis of psoriasis; yet the underlying molecular mechanisms driving the development of the disease are still largely elusive...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28050487/safety-and-efficacy-of-itolizumab-in-the-treatment-of-psoriasis-a-case-series-of-20-patients
#6
Anchala Parthasaradhi
Psoriasis is a common, chronic, relapsing/remitting, immune-mediated skin disease that causes itchy skin with silvery scales. It is characterized by thickened red erythematous plaques covered with silvery scales. Biological therapies have been recently introduced for patients with psoriasis in India. The biological therapies contain protein biomolecules which can be employed to target specific immune or genetic mediator of a pathophysiological process. Here, we share our clinical experience of managing 20 patients with moderate to severe psoriasis by itolizumab a humanized IgG1 monoclonal antibody...
November 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28043870/il-1-and-il-36-are-dominant-cytokines-in-generalized-pustular-psoriasis
#7
Andrew Johnston, Xianying Xing, Liza Wolterink, Drew H Barnes, ZhiQiang Yin, Laura Reingold, J Michelle Kahlenberg, Paul W Harms, Johann E Gudjonsson
BACKGROUND: Generalized pustular psoriasis (GPP) is a rare, debilitating, and often life-threatening inflammatory disease characterized by episodic infiltration of neutrophils into the skin, pustule development, and systemic inflammation, which can manifest in the presence or absence of chronic plaque psoriasis (PV). Current treatments are unsatisfactory warranting a better understanding of GPP pathogenesis. OBJECTIVE: To understand better the disease mechanism of GPP to allow improved targeted therapies...
December 30, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#8
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
January 18, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28035222/serum-vitamin-d-level-the-effect-on-the-clinical-course-of-psoriasis
#9
Beata Bergler-Czop, Ligia Brzezińska-Wcisło
INTRODUCTION: Psoriasis is a hyperproliferative disorder of the skin, and vitamin D analogs are widely used in its treatment. It is evident that ultraviolet radiation enables vitamin D3 (cholecalciferol) formation in the epidermis, and this product is further converted into the active metabolites 25-hydroxycholecalciferol and 1,25-hydroxycholecalciferol, which exert several important effects on the skin. The disruption in proper functioning of the skin which occurs in psoriasis leads to a loss of capacity for cutaneous synthesis of vitamin D3...
December 2016: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28035220/contribution-of-myeloperoxidase-and-inducible-nitric-oxide-synthase-to-pathogenesis-of-psoriasis
#10
Nursel Dilek, Aziz Ramazan Dilek, Yakup Taşkın, Taşkın Erkinüresin, Ömer Yalçın, Yunus Saral
INTRODUCTION: Histological changes of psoriasis include invasion of neutrophils into the epidermis and formation of Munro abscesses in the epidermis. Neutrophils are the predominant white blood cells in circulation when stimulated; they discharge the abundant myeloperoxidase (MPO) enzyme that uses hydrogen peroxide to oxidize chloride for killing ingested bacteria. AIM: To investigate the contribution of neutrophils to the pathogenesis of psoriasis at the blood and tissue levels through inducible nitric oxide synthase (iNOS) and MPO...
December 2016: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/28012564/an-intensified-dosing-schedule-of-subcutaneous-methotrexate-in-patients-with-moderate-to-severe-plaque-type-psoriasis-metop-a-52-week-multicentre-randomised-double-blind-placebo-controlled-phase-3-trial
#11
Richard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, Johannes Niesmann, Dagmar Wilsmann-Theis, Kamran Ghoreschi, Ina Zschocke, Thomas M Falk, Norbert Blödorn-Schlicht, Kristian Reich
BACKGROUND: Methotrexate is one of the most commonly used systemic drugs for the treatment of moderate to severe psoriasis; however, high-quality evidence for its use is sparse and limited to use of oral dosing. We aimed to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis. METHODS: We did this prospective, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (METOP) at 16 sites in Germany, France, the Netherlands, and the UK...
December 21, 2016: Lancet
https://www.readbyqxmd.com/read/27998019/optimizing-acitretin-use-in-patients-with-plaque-psoriasis
#12
Andrea Chiricozzi, Salvatore Panduri, Valentina Dini, Annalisa Tonini, Bruno Gualtieri, Marco Romanelli
Acitretin is one of the systemic agents used for the treatment of psoriasis. Because different acitretin dosages resulted therapeutically successful, there is no general agreement on the optimal dose regimen. To report acitretin efficacy and safety in a real-life setting, wherein patient-tailored dose regimen is usually prescribed, a retrospective analysis evaluating charts of all plaque-type psoriasis patients treated with acitretin from the clinic database was performed. PASI score improvement, as well as PASI 50, 75, 90, and 100 responses were assessed throughout the observational period...
December 20, 2016: Dermatologic Therapy
https://www.readbyqxmd.com/read/27995617/prevalence-of-alexithymia-in-patients-with-psoriasis-and-its-association-with-disease-burden-a-multicentre-observational-study
#13
F Sampogna, L Puig, P Spuls, G Girolomoni, M A Radtke, B Kirby, M Brunori, P Bergmans, P Smirnov, J Rundle, F Lavie, C Paul
BACKGROUND: Single-centre studies show that alexithymia, defined as difficulty in recognizing and describing emotions, is more prevalent among psoriasis patients than in the general population. However, its prevalence and the consequences of the association between alexithymia and psoriasis are unclear. OBJECTIVES: The primary objective of this study was to determine the prevalence of alexithymia, as defined by a score ≥61 in the 20-item Toronto Alexithymia Scale (TAS-20), in a large sample of patients who had plaque psoriasis for ≤10 years and were eligible for phototherapy or systemic treatment...
December 20, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27995521/efficacy-and-safety-of-calcipotriol-plus-betamethasone-dipropionate-aerosol-foam-compared-with-betamethasone-17-valerate-medicated-plaster-for-the-treatment-of-psoriasis
#14
Catherine Queille-Roussel, Monika Rosen, Fabrice Clonier, Kasper Nørremark, Jean-Philippe Lacour
BACKGROUND: Fixed combination calcipotriol as hydrate (Cal) 50 µg/g plus betamethasone as dipropionate (BD) 0.5 mg/g aerosol foam is an alcohol-free treatment for psoriasis. Betamethasone 17-valerate 2.25 mg (BV)-medicated plasters are recommended for treating psoriasis plaques localized in difficult-to-treat (DTT; elbow, knee, anterior face of the tibia) areas. OBJECTIVE: The aim of this study was to compare the efficacy of Cal/BD foam with BV-medicated plaster in patients with plaque psoriasis...
December 19, 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27990383/biologics-use-in-indian-psoriasis-patients
#15
Murlidhar Rajagopalan, Asit Mital
The biologics currently in use for psoriasis in India are etanercept, infliximab and recently introduced itolizumab and secukinumab. Biosimilars, expected to play a significant role in psoriasis management in future, have also been available for the last few years. Patients with psoriasis may be considered eligible to receive treatment with any of the licensed biologic interventions when they fulfill the eligibility criteria. The decision to proceed with treatment must be made in collaboration with the patient and include a careful assessment of the associated risks and benefits...
November 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27990381/psoriasis-epidemiology-clinical-features-co-morbidities-and-clinical-scoring
#16
Sunil Dogra, Rahul Mahajan
On the basis of current evidence derived from hospital-based studies, mostly from North India, the prevalence of psoriasis in adults varies from 0.44 to 2.8%, with a much lower prevalence in children. The peak age at onset in adults is in the third and fourth decade of life, with a slight male preponderance. It is recommended that population-based large epidemiologic studies should be undertaken in different parts of the country for estimating the correct prevalence of psoriasis in general population. Chronic plaque-type psoriasis is the most common morphologic presentation of psoriasis, accounting for more than 90% of all cases...
November 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27988894/increase-in-circulating-sphingosine-1-phosphate-and-decrease-in-ceramide-levels-in-psoriatic-patients
#17
Hanna Myśliwiec, Anna Baran, Ewa Harasim-Symbor, Barbara Choromańska, Piotr Myśliwiec, Anna Justyna Milewska, Adrian Chabowski, Iwona Flisiak
Psoriasis is characterized by hyperproliferation, deregulated differentiation and impaired apoptosis of keratinocytes. Mechanisms of lipid profile disturbances and metabolic syndrome in the psoriatic patients are still not fully understood. Sphingolipids, namely ceramides (CER) and sphingosine-1-phosphate (S1P) are signal molecules which can regulate cell growth, apoptosis and immune reactions. The aim of the study was to evaluate circulating CER and S1P levels in plaque-type psoriasis and their associations with the disease activity, inflammatory or metabolic markers and the presence of psoriatic comorbidities...
December 17, 2016: Archives of Dermatological Research
https://www.readbyqxmd.com/read/27977334/pharmacogenetics-of-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis
#18
Rocío Prieto-Pérez, Mar Llamas-Velasco, Teresa Cabaleiro, Guillermo Solano-López, Beatriz Márquez, Manuel Román, Dolores Ochoa, María Talegón, Esteban Daudén, Francisco Abad-Santos
: Aim/Materials & methods: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We evaluated 121 polymorphisms to study a possible association between these SNPs and the response to ustekinumab (PASI75 at 4 months; n = 69). RESULTS/CONCLUSION: The adjusted results (false discovery rate) showed an association between five SNPs in TNFRSF1A, HTR2A, NFKBIA, ADAM33 and IL13 genes, and poor response to ustekinumab...
January 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/27973689/inequalities-in-access-to-biological-treatments-for-psoriasis-results-from-the-italian-psocare-registry
#19
L Naldi, S Cazzaniga, M di Mercurio, E Grossi, A Addis
BACKGROUND: Limited evidence is available on the impact of socioeconomic factors in drug prescriptions for psoriasis. OBJECTIVES: To investigate factors influencing prescription of conventional versus biological treatment for psoriatic patients, based on the Psocare registry with a special focus on socioeconomic factors. METHODS: This was a cross-sectional study evaluating the baseline data of patients included in the Italian Psocare Registry...
December 14, 2016: British Journal of Dermatology
https://www.readbyqxmd.com/read/27971733/cost-effectiveness-analysis-of-secukinumab-compared-to-current-biologics-sequences-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-france
#20
E Duteil, C Cariou, A Schmidt, K Benjamin, J Duco
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"